Company intelligence / Profile preview
Helix Nanotechnologies
Cambridge, Massachusetts, United Stateshelixnano.com ↗
- Ownership
- Private
- Employees
- ~22
- Development stage
- Other
01
Overview
Helix Nanotechnologies has advanced its lead COVID-19 mRNA vaccine (HN-0001) into Phase I clinical trials in Australia, showing initial safety and supporting its approach of stable RNA formats with novel delivery methods. Preclinical programs target cancer immunotherapy and transplant rejection, with an expanding infectious disease pipeline.[1]
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- mRNA-based drugsNanoparticleVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Medicus Pharma (co-developing thermostable mRNA vaccines with microneedle delivery)
Beyond the preview
Go deeper on Helix Nanotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helix Nanotechnologies.